ENTX
NASDAQEntera Bio Ltd.
News · 26 weeks39-29%
2025-10-262026-04-19
Mix2590d
- Other9(36%)
- Insider9(36%)
- SEC Filings6(24%)
- Leadership1(4%)
Latest news
25 items- PRBriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet OpportunityIn a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (NASDAQ:ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 - being developed as the first and only oral anabolic (bone-forming) tablet for osteoporosis. The discussion featured Dr. Felicia Cosman, Professor of Medicine at Columbia University and a globally recognized authority in osteoporosis and anabolic therapies, and Dr. Steven Goldstein, Professor of Obstetrics and Gynecology at NYU Grossman School of Medicine and former President of both the International Menopause Soci
- PREntera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April 20, 2026 at 11:00 AM Eastern Time. Attendance for the event requires registration. Participants may register at the following link: https://events.zoom.us/ev/AjJwNRe2lJ20ip76GJ4k0Ee_SLHBTKEcb9Iabu7PDwVyGRBCzqr_~AqIJON0d6_lhurfYvEmThe3o4X3G0iFAy9zFmuBnQMCqifflBtC23k66Fg The roundt
- PRGreenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF PartnersMIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd. (NASDAQ:ENTX), a clinical-stage biotechnology company focused on the development of oral peptide and protein replacement therapies, in a $10 million private placement led by funds affiliated with private investment firm BVF Partners L.P. Under the terms of the transaction, which closed April 2, Entera issued and sold an aggregate of 7,827,789 units at a purchase price of $1.2775 per unit, according to the company's press release. Each unit consists of one ordinary sh
- SECEntera Bio Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total ProceedsTEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement for a private placement (the "Private Placement") led by funds affiliated with BVF Partners L.P. ("BVF"). The Private Placement is expected to close on or about April 2, 2026, subject to customary closing conditions. Pursuant to the Private Placement, the Company agreed to issue and sell an aggregate of 7,827,789 units (the "Units") at a purchase price of $1.2775 per Unit. Each Unit consists of (i) one ordinary share of Entera (or, in lieu thereof, one pre-funde
- SECSEC Form 10-K filed by Entera Bio Ltd.10-K - Entera Bio Ltd. (0001638097) (Filer)
- SECEntera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Bio Announces Full Year 2025 Financial Results and Provides Business UpdatesEB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, the first long-acting oral PTH peptide replacement tablet for patients with hypoparathyroidism - final variants selected, pre-IND initiatives underway with intention to file IND in late 2026 in partnership with OPKO EB618, the first Oral OXM (GLP-1/Glucagon) peptide tablet for patients with metabolic syndromes – PK/PD validation complete, intention to file IND pursuant to OPKO Phase 1 SAD/MAD SC injection data TEL AVIV, March 27, 2026 (GLOBE NEWSWIRE) -
- INSIDERDirector Germano Geno J bought $26,000 worth of Ordinary Shares (20,000 units at $1.30), increasing direct ownership by 100% to 40,000 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Ellis Sean bought $12,300 worth of Ordinary Shares (10,000 units at $1.23), increasing direct ownership by 6% to 188,098 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- SECEntera Bio Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with OsteoporosisPhase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected; Entera commits to a 12-month extension study to run in parallel with potential NDA review TEL AVIV, March 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced the submission to the U.S. Food and D
- PREntera Bio to Participate in the Leerink Partners 2026 Global Healthcare ConferenceTEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the Leerink Partners Global Healthcare Conference 2026, details as below. Leerink Partners Global Healthcare Conference 2026 (Fireside Chat and 1x1 Meetings) Date and Time: March 11, 2026 at 10:40 a.m. Eastern TimeLocation: In person, March 8–11, 2026, W South Beach, Miami, Florida A live webcast of the discussion, including presentation slides, will be available at the link below. A repl
- INSIDERDirector Rubin Steven D bought $7,450 worth of Ordinary Shares (5,000 units at $1.49), increasing direct ownership by 50% to 15,000 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- PREntera Bio Announces Open Market Purchases of Company Stock by Board MembersTEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company's Chairman, have made open market purchases of the Company's ordinary shares. These transactions follow an earlier open market purchase by Entera Bio's Chief Executive Officer, Miranda Toledano, in December 2025. The purchases were made by Geno J. Germano, Chairman of the Board; Steven D. Rubin, Director; Haya Taitel, Director; and Sean Ellis, Director. The shares were acquired in open market transactions at prevailing market
- INSIDERDirector Taitel Haya bought $11,100 worth of Ordinary Shares (7,500 units at $1.48), increasing direct ownership by 8% to 98,479 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Germano Geno J bought $29,800 worth of Ordinary Shares (20,000 units at $1.49) (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Rubin Steven D bought $12,000 worth of Ordinary Shares (10,000 units at $1.20) (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Ellis Sean bought $22,320 worth of Ordinary Shares (18,000 units at $1.24), increasing direct ownership by 11% to 178,098 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERSEC Form 3 filed by new insider Germano Geno J3 - Entera Bio Ltd. (0001638097) (Issuer)
- PREntera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key MilestonesTEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026. Mr. Germano succeeds Gerald Lieberman, who is stepping down as Chairman. The appointment follows a period of accelerating progress across Entera's pipeline as the Company plans to advance two oral PTH peptide programs into clinical testing within 2026, a Phase 3 registrational study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism. "
- SECEntera Bio Ltd. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Entera Bio Ltd. (0001638097) (Filer)
- INSIDERSEC Form 3 filed by new insider Rubin Steven D3 - Entera Bio Ltd. (0001638097) (Issuer)
- SECEntera Bio Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Entera Bio Ltd. (0001638097) (Filer)
- PROPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with HypoparathyroidismThis is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter Industry veteran Steve Rubin joins Entera's board MIAMI and TEL AVIV, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO